Zelluna Immunotherapy: Funding, Investors & Team (Sep 2026)
Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on the development of TCR based immunotherapies. Our goal is to revolutionize cancer therapy by developing TCR based therapies with the potential to treat a wide range of cancer types and patients. Zelluna’s core asset is a wide range of TCRs isolated from patients who exhibited long-term survival following inclusion in peptide based cancer vaccine trials initiated by Prof Gustav Gaudernack and conducted by investigators at the Norwegian Radium Hospital/Oslo University Hospital. Currently the company has several TCRs in different stages of development. We are a member of Oslo Cancer Cluster (Norwegian Centre of Expertise), a member organization for Norwegian and International stakeholders within cancer research and development. Oslo Cancer Cluster has members from the biotechnology industry, the government, patient organizations, research institutions and hospitals. Zelluna is located at the Oslo Cancer Cluster Innovation Park, next to the Norwegian Radium Hospital/Oslo University Hospital, the Department for Cellular Therapy and one of Europe’s largest academic certified GMP facilities for cellular products.
Zelluna Immunotherapy has raised $6.2M across 3 funding rounds on record, the most recent an undisclosed round of $1.6M announced in Jun 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Zelluna Immunotherapy Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Zelluna Immunotherapy Funding Rounds
1 of 3 rounds was announced without a disclosed amount and is excluded from the total.
Zelluna Immunotherapy announced an undisclosed round in Aug 2022; the amount was not disclosed.
2.6 years later, an undisclosed round of $4.6M was announced in Mar 2025.
1.3 years later, an undisclosed round of $1.6M was announced in Jun 2026.
Zelluna Immunotherapy Founders and Leadership Team
Contact details for the Zelluna Immunotherapy team: 1 of 2 have an email address on file.
Start 14-day free trial →Zelluna Immunotherapy Funding Compared to Other Biotechnology Startups
Zelluna Immunotherapy's latest round of $1.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Zelluna Immunotherapy in Biotechnology and Oslo
Companies Similar to Zelluna Immunotherapy
Hofseth BioCare's key goal is to offer high benefit added biomarine elements for human applications. Through…
Circio Holding ASA is a company in the clinical stage that is developing immune activators for challenging…
IDEX, a biometrics software and fingerprint authentication company based in Oslo, Norway, was established in…
Arctic Bioscience is a biotechnology research company that develops products, solutions, and technologies…
Lytix Biopharma AS is a privately-owned pharmaceutical company focussed on anti-microbials and cancer…
Actithera is a company specializing in developing radioligand therapies through the application of medicinal…
NoMy is a company focused on creating sustainable and scalable solutions for alternative proteins by…
Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of…
Biosergen AS develops variants of nystatin with improved properties. Its pipeline products include S44HP, an…
NEXT offers secure and user-friendly fingerprint sensor technology for verification purposes in various…
We are a speciality pharmaceutical business committed to the creation and marketing of goods for people who…
Calluna has developed a robust pipeline of selective antibodies, targeting immunological diseases. These…
Zelluna Immunotherapy Funding FAQs
What does Zelluna Immunotherapy do?
Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on the development of TCR based immunotherapies. Our goal is to revolutionize cancer therapy by developing TCR based therapies with the potential to treat a wide range of cancer types and patients. Zelluna’s core asset is a wide range of TCRs isolated from patients who exhibited long-term survival following inclusion in peptide based cancer vaccine trials initiated by Prof Gustav Gaudernack and conducted by investigators at the Norwegian Radium Hospital/Oslo University Hospital. Currently the company has several TCRs in different stages of development. We are a member of Oslo Cancer Cluster (Norwegian Centre of Expertise), a member organization for Norwegian and International stakeholders within cancer research and development. Oslo Cancer Cluster has members from the biotechnology industry, the government, patient organizations, research institutions and hospitals. Zelluna is located at the Oslo Cancer Cluster Innovation Park, next to the Norwegian Radium Hospital/Oslo University Hospital, the Department for Cellular Therapy and one of Europe’s largest academic certified GMP facilities for cellular products.
How much funding has Zelluna Immunotherapy raised?
Zelluna Immunotherapy has raised $6.2M across 3 rounds on record. The most recent is an undisclosed round of $1.6M announced in Jun 2026.
When did Zelluna Immunotherapy last raise funding?
Zelluna Immunotherapy's most recent funding round on record is an undisclosed round of $1.6M, announced in Jun 2026.
Who founded Zelluna Immunotherapy?
FundedIQ lists Hans Ivar Robinson (Founder), Namir Hassan (Founder) at Zelluna Immunotherapy.
Where is Zelluna Immunotherapy headquartered?
Zelluna Immunotherapy is based in Oslo, Norway.
How many employees does Zelluna Immunotherapy have?
Zelluna Immunotherapy is in the 11-50 employee band.
How does Zelluna Immunotherapy's funding compare to other Biotechnology startups?
Zelluna Immunotherapy's latest round of $1.6M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Zelluna Immunotherapy Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Zelluna Immunotherapy is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.